1015 Capital Partners’s Roivant Sciences ROIV Stock Holding History

1015 Capital Partners’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$319	Buy	+9	New	+$266	﹤0.01%	565

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

1015 Capital Partners's ROIV Position: Q2 2026 in Review

1015 Capital Partners opened a new position in Roivant Sciences (ROIV) in Q2 2026: 9 shares worth $319. The stake represents ﹤0.01% of the portfolio and ranks #565 among its holdings.

496 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

1015 Capital Partners held 9 shares of Roivant Sciences worth $319 as of Q2 2026.
Roivant Sciences was a new 1015 Capital Partners position in Q2 2026.
Roivant Sciences made up ﹤0.01% of 1015 Capital Partners's portfolio in Q2 2026, its #565 holding.
496 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on 1015 Capital Partners's 13F filing for Q2 2026, filed 21 Jul 2026.